Table of Contents
Chapter 1. Global Plasma Protease C1-Inhibitor Market Definition and Research Assumptions
1.1. Research Objective
1.2. Market Definition
1.3. Research Assumptions
1.3.1. Inclusion & Exclusion
1.3.2. Limitations
1.3.3. Supply Side Analysis
1.3.3.1. Availability
1.3.3.2. Infrastructure
1.3.3.3. Regulatory Environment
1.3.3.4. Market Competition
1.3.3.5. Economic Viability (Consumer's Perspective)
1.3.4. Demand Side Analysis
1.3.4.1. Regulatory frameworks
1.3.4.2. Technological Advancements
1.3.4.3. Environmental Considerations
1.3.4.4. Consumer Awareness & Acceptance
1.4. Estimation Methodology
1.5. Years Considered for the Study
1.6. Currency Conversion Rates
Chapter 2. Executive Summary
2.1. Global Plasma Protease C1-Inhibitor Market Size & Forecast (2022- 2032)
2.2. Regional Summary
2.3. Segmental Summary
2.3.1. By Drug Type
2.3.2. By Dosage Form
2.4. Key Trends
2.5. Recession Impact
2.6. Analyst Recommendation & Conclusion
Chapter 3. Global Plasma Protease C1-Inhibitor Market Dynamics
3.1. Market Drivers
3.2. Market Challenges
3.3. Market Opportunities
Chapter 4. Global Plasma Protease C1-Inhibitor Market: Industry Analysis
4.1. Porter's 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter's 5 Force Model
4.1.7. Porter's 5 Force Impact Analysis
4.2. PESTEL Analysis
4.2.1. Political
4.2.2. Economic
4.2.3. Social
4.2.4. Technological
4.2.5. Environmental
4.2.6. Legal
4.3. Top investment opportunity
4.4. Top winning strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion
Chapter 5. Global Plasma Protease C1-Inhibitor Market Size & Forecasts by Drug Type 2022-2032
5.1. C1-inhibitors
5.2. Kallikrein Inhibitor
5.3. Selective Bradykinin B2 Receptor Antagonist
Chapter 6. Global Plasma Protease C1-Inhibitor Market Size & Forecasts by Dosage Form 2022-2032
6.1. Lyphophlised
6.2. Injectables
Chapter 7. Global Plasma Protease C1-Inhibitor Market Size & Forecasts by Region 2022-2032
7.1. North America Plasma Protease C1-Inhibitor Market
7.1.1. U.S. Plasma Protease C1-Inhibitor Market
7.1.1.1. Drug Type breakdown size & forecasts, 2022-2032
7.1.1.2. Dosage Form breakdown size & forecasts, 2022-2032
7.1.2. Canada Plasma Protease C1-Inhibitor Market
7.2. Europe Plasma Protease C1-Inhibitor Market
7.2.1. U.K. Plasma Protease C1-Inhibitor Market
7.2.2. Germany Plasma Protease C1-Inhibitor Market
7.2.3. France Plasma Protease C1-Inhibitor Market
7.2.4. Spain Plasma Protease C1-Inhibitor Market
7.2.5. Italy Plasma Protease C1-Inhibitor Market
7.2.6. Rest of Europe Plasma Protease C1-Inhibitor Market
7.3. Asia-Pacific Plasma Protease C1-Inhibitor Market
7.3.1. China Plasma Protease C1-Inhibitor Market
7.3.2. India Plasma Protease C1-Inhibitor Market
7.3.3. Japan Plasma Protease C1-Inhibitor Market
7.3.4. Australia Plasma Protease C1-Inhibitor Market
7.3.5. South Korea Plasma Protease C1-Inhibitor Market
7.3.6. Rest of Asia Pacific Plasma Protease C1-Inhibitor Market
7.4. Latin America Plasma Protease C1-Inhibitor Market
7.4.1. Brazil Plasma Protease C1-Inhibitor Market
7.4.2. Mexico Plasma Protease C1-Inhibitor Market
7.4.3. Rest of Latin America Plasma Protease C1-Inhibitor Market
7.5. Middle East & Africa Plasma Protease C1-Inhibitor Market
7.5.1. Saudi Arabia Plasma Protease C1-Inhibitor Market
7.5.2. South Africa Plasma Protease C1-Inhibitor Market
7.5.3. Rest of Middle East & Africa Plasma Protease C1-Inhibitor Market
Chapter 8. Competitive Intelligence
8.1. Key Company SWOT Analysis
8.2. Top Market Strategies
8.3. Company Profiles
8.3.1. CSL Limited (CSL Behring LLC)
8.3.1.1. Key Information
8.3.1.2. Overview
8.3.1.3. Financial (Subject to Data Availability)
8.3.1.4. Product Summary
8.3.1.5. Market Strategies
8.3.2. Takeda Pharmaceutical Company Limited (Shire Pharmaceutical Holdings)
8.3.3. Ionis Pharmaceuticals, Inc.
8.3.4. Pharming Technologies B.V.
8.3.5. Centogene AG
8.3.6. BioCryst Pharmaceuticals
8.3.7. KalVista Pharmaceuticals, Inc.
8.3.8. Fresenius Kabi
8.3.9. Octapharma AG
8.3.10. Kedrion S.p.A.
Chapter 9. Research Process
9.1. Research Process
9.1.1. Data Mining
9.1.2. Analysis
9.1.3. Market Estimation
9.1.4. Validation
9.1.5. Publishing
9.2. Research Attributes